In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

Int J Antimicrob Agents. 2006 Nov;28(5):385-8. doi: 10.1016/j.ijantimicag.2006.07.017.

Abstract

An initiative was taken to determine the in vitro activity of daptomycin against 85 Gram-positive isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Daptomycin had potent activity against all strains, with a Staphylococcus spp. minimum inhibitory concentration (MIC) < or =2 microg/mL and an Enterococcus spp. MIC < or =8 microg/mL. Resistance to linezolid and quinupristin/dalfopristin appears to be independent of reduced susceptibility to daptomycin.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacology
  • Daptomycin / pharmacology*
  • Drug Resistance, Bacterial
  • Enterococcus faecalis / drug effects
  • Enterococcus faecium / drug effects
  • Gram-Positive Bacteria / drug effects*
  • Humans
  • Linezolid
  • Oxazolidinones / pharmacology*
  • Staphylococcus aureus / drug effects
  • Virginiamycin / pharmacology*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Virginiamycin
  • quinupristin-dalfopristin
  • Linezolid
  • Daptomycin